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Endovascular therapy in prevention and
management of coronary-subclavian steal
Alex Westerband, MD, Julio A. Rodriguez, MD, Venkatesh G. Ramaiah, MD, and Edward B. Diethrich,
MD, Phoenix, Ariz
Background: The optimal management of patients undergoing coronary artery bypass grafting (CABG) who have
proximal subclavian artery stenosis (SAS) is not well established. SAS may lead to flow reversal through a patent in situ
internal mammary artery graft, resulting in myocardial ischemia (coronary-subclavian steal). We review our experience in
prevention and management of coronary-subclavian steal.
Methods: The medical records of patients who received treatment of symptomatic coronary-subclavian steal were reviewed.
Patients who underwent subclavian artery revascularization before CABG were also included in our review. Patient
demographic data, findings at presentation, imaging and treatment methods, and short-term and intermediate-term
results were analyzed.
Results: Over 4 years, 14 patients with combined subclavian and coronary artery disease were identified. Nine patients had
angina (n  8) and/or congestive heart failure (n  2) after CABG (post-CABG group). Four patients underwent
treatment of SAS and one underwent treatment of recurrent stenosis before or during CABG (pre-CABG group). Among
this pre-CABG group, one patient had symptoms of left arm claudication; the other four patients had no symptoms. A
blood pressure gradient was commonly noted between both arms. An angiogram confirmed the proximal location of SAS
in all patients, and established the presence of flow reversal in a patent internal mammary artery graft in the post-CABG
group. Operative management consisted of percutaneous transluminal angioplasty (PTA) and stenting of the subclavian
lesion in 11 patients, PTA only in 2 patients, and carotid-subclavian bypass grafting in 1 patient. No known perioperative
complications or morbidity was encountered in either group. Mean follow-up was 29 months, during which stenosis
recurred in two patients, along with associated cardiac symptoms. In both patients repeat angioplasty was successful, for
an assisted primary patency rate of 100%.
Conclusion: PTA and stenting to treat SAS appears to provide effective protection from and treatment of coronary-
subclavian steal over the short and intermediate terms. A surveillance program is essential because of the risk for recurrent
stenosis. Continued follow-up is necessary to determine long-term efficacy of this treatment compared with more
conventional surgical approaches. (J Vasc Surg 2003;38:699-704.)
According to the guidelines of the American College
of Cardiology and the American Heart Association for
coronary artery bypass grafting (CABG), the left internal
mammary artery is the conduit of choice for bypass to the
left anterior descending artery.1 While the left internal
mammary artery is often considered relatively protected
from atherosclerosis because of its freedom from major
occlusive lesions, in most cases,2,3 and its excellent long-
term patency rate,4 the same observation does not apply
to its parent (inflow) vessel, the left subclavian artery. On
the basis of angiographic and clinical studies, the inci-
dence of subclavian stenosis in patients undergoing
CABG ranges from 0.5% to 1.1%.5-7 Proximal left sub-
clavian stenosis can lead to reversal of flow in a patent left
internal mammary artery graft, known as coronary-sub-
clavian steal, resulting in myocardial ischemia.8,9 More
than a decade ago this potentially lethal condition first
prompted the medical community to recommend against the
use of the internal mammary artery for CABG in patients with
ipsilateral subclavian artery stenosis (SAS) preoperatively.3
During that period, coronary steal was successfully managed
with carotid-subclavian artery bypass.8,10-14 A few patients
underwent simultaneous direct reconstruction of the left sub-
clavian artery at coronary revascularization.15 Over the ensu-
ing years, as use of the left internal mammary artery as the
bypass conduit of choice for CABG continued to increase, so
did the incidence of coronary-subclavian steal, although this
syndrome remains uncommon.8 In addition, new therapeutic
alternatives have emerged, including management of coro-
nary-subclavian steal with percutaneous transluminal angio-
plasty (PTA) with or without stenting.16-18 In 1995 Diethrich
and Cozacov19 reported coronary-subclavian steal that they
had successfully treated 1 year earlier with primary stenting,
and the patient had remained free of coronary steal symptoms
for more than a year.
We report the experience accumulated at a single insti-
tution for prevention or treatment of subclavian-coronary
steal since hospital inauguration in 1997.
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METHODS
Medical records were reviewed for patients with coro-
nary subclavian steal treated at the Arizona Heart Hospital,
Phoenix, during over 4 consecutive years. Patients with
significant SAS requiring treatment before CABG were also
included in the review. Patient demographic data, clinical
findings, methods of diagnosis, and type of revasculariza-
tion procedure were analyzed. An endovascular approach,
when feasible, is the preferred method at this institution.
Subclavian artery occlusive lesions that cannot be crossed
with a guide wire are treated with carotid-subclavian bypass
grafting.
Endovascular technique. Details of the interven-
tional technique used by vascular surgeons from the Ari-
zona Heart Institute for treatment of SAS have been de-
scribed.20 In brief, all procedures were performed in the
endovascular operative suite with the patient under either
general or local anesthesia. In all patients, a transradial
blood pressure monitoring line was placed in the opposite
side to accurately compare blood pressure values between
both upper extremities before and after treatment. A 6F or
7F sheath was used. Fluoroscopic guidance and road-map-
ping were used in all cases. Typically, the lesion was crossed
with a 0.035-inch angled hydrophilic guide wire (Glide-
wire; MediTech/Boston Scientific, Watertown, Mass). The
lesion was generally predilated with an angioplasty balloon
(size, 5-8 mm), followed by deployment of a balloon-
expandable stent in most cases (Figure). Stent size was
selected on the basis of size of the adjacent normal subcla-
vian artery. Post-stenting dilation was performed anytime
there was residual stenosis. After PTA and stenting of SAS,
patients were given a combination of aspirin (325 mg once
daily) and dipyridamole (50 mg twice daily) for 1 month,
then aspirin over the long term. More recently, however,
only aspirin is being used by many after angioplasty and
stenting of the subclavian artery performed to treat
stenosis.
Clinical follow-up was by means of routine outpatient
examination, with blood pressure measurement in both
upper extremities, and, at times, duplex ultrasound scan-
ning of the treated subclavian artery. Patients came for a
follow-up visit with the vascular surgeon 1 to 2 weeks after
the procedure. Subsequently, most were followed up by
their primary care provider or cardiologist, on average twice
a year. Those followed up by a cardiologist were most likely
to undergo duplex scanning. Follow-up information was
obtained from practitioners’ data files at the Arizona Heart
Institute and from communication with the patients, their
families, or their family physicians when possible. Signifi-
cant recurrent stenosis corresponded to 50% or greater
stenosis, as defined by the Ad Hoc Subcommittee on
Reporting Standards of the Society for Vascular Surgery
and the North American Chapter of the International
Society of Cardiovascular Surgery.21,22 Life-table analysis
of all endovascular interventions was performed to assess
durability of this method of therapy.
RESULTS
Review of hospital records for all patients who under-
went treatment of SAS or occlusion identified 14 patients
with concomitant subclavian and coronary artery disease
treated between March 1997 and November 2001. Of
Left, Arteriogram shows 70% left subclavian artery stenosis proximal to the origin of an in situ left internal mammary
artery graft. Right, Arteriogram obtained after balloon angioplasty and stenting shows no residual stenosis.
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these patients, eight were men and six were women, and
mean age was 69 years (range, 49-80 years). Comorbid
conditions are listed in Table I. Among patients with cere-
brovascular disease, two had undergone previous bilateral
carotid endarterectomy. Six other patients had evidence of
carotid artery disease according to duplex criteria (16%-
49%). In two patients, duplex scans revealed retrograde
flow in the left vertebral artery. None of the 14 patients had
symptoms of vertebrobasilar insufficiency. One patient in
the pre-CABG group had undergone angioplasty more
than a year previously, because of stenosis of the left sub-
clavian artery.
At presentation, nine patients had either angina (n 8)
or congestive heart failure (n  2) after CABG (post-
CABG group). On average, coronary steal after CABG was
noted at 14 years (range, 2-31 years). Among this group,
two patients had undergone repeat CABG. Four additional
patients underwent treatment of SAS, and one patient
underwent treatment of recurrent stenosis before or at
CABG (pre-CABG group). In the pre-CABG group, one
patient had symptoms of left arm claudication; the remain-
ing four patients had no symptoms of left arm ischemia or
vertebrobasilar steal.
A blood pressure discrepancy between arms was typi-
cally noted in all patients in the pre-CABG group, whereas
it was not significant in two of nine patients in the post-
CABG group. Mean blood pressure gradient between the
left and right arms was 32 28.04 mm Hg in both groups.
Arteriography definitely established the diagnosis of subcla-
vian occlusive disease in all 14 patients. In the post-CABG
group, eight patients had 60% to 90% proximal SAS and
one patient had complete occlusion; flow reversal was
present in a left internal mammary artery graft in all nine
patients. In the five patients in the pre-CABG group,
degree of stenosis as determined on arteriograms was 50%
in one patient, 70% in two patients, 75% in one patient, and
95% in one patient. No occlusion was present preopera-
tively in this group. Intent-to-treat was by endovascular
means in all patients. Procedures were carried out with the
patient under local anesthesia, with intravenous sedation in
four patients, general anesthesia with laryngeal mask airway
in nine patients, and intubation before carotid-subclavian
bypass grafting in one patient.
In the post-CABG group, some patients were directly
transferred from the cardiac catheterization laboratory with
either a femoral sheath or a brachial sheath in place after
internal mammary artery flow reversal along with proximal
SAS. The left brachial artery was the access site in 12
patients, and was also used for concomitant management of
coronary vein graft stenosis in 1 patient and right renal
artery stenosis in 2 patients with renovascular hypertension.
The left common femoral artery was used as an access site in
two patients, and was also used for angioplasty and stenting
of left external iliac artery stenosis in one patient with left
lower extremity claudication. These additional procedures
were performed at the same setting after successful treat-
ment of SAS.
A 6F sheath was used in 10 patients, and a 7F sheath in
the remainder. The lesion was crossed successfully in all
patients except one, with complete occlusion. A balloon-
expandable stent was used in nine patients (Figure), and a
self-expandable stent in one patient. Post-stenting dilation
was performed because of residual stenosis in eight patients,
with correction of the stenosis. One patient underwent
balloon angioplasty only; no stent was used, because, in the
opinion of the surgeon, the results were excellent, with no
residual gradient and no recoil after angioplasty. Another
patient with post-stenting residual stenosis before CABG
underwent balloon angioplasty only. In one patient with
complete occlusion, the lesion could not be crossed despite
numerous attempts, and this patient underwent left carot-
id-subclavian bypass grafting with a polytetrafluoroethyl-
ene graft.
Follow-up. The endovascular procedure was techni-
cally successful in 13 of 14 patients, with correction of any
pressure gradient and resolution of the coronary steal phe-
nomenon in the post-CABG group. All patients in the
post-CABG group immediately experienced relief of angina
after correction of SAS. There was no stroke or access site
thrombosis. No perioperative morbidity or mortality was
noted. In one patient, a bruit has developed over the
brachial artery access site, which was not noted periopera-
tively; however, the condition has remained asymptomatic,
with no treatment.
At mean follow-up of 29 months (median, 33.6
months; range, 6-51 months), clinically significant stent
recurrent stenosis was detected in two patients. One patient
had angina, and clinical evidence of congestive heart failure
and recurrent coronary-subclavian steal. Examination re-
vealed a 32-mm systolic blood pressure gradient between
the right and left arms. After angiographic confirmation,
the recurrently stenotic lesion was successfully treated with
balloon angioplasty. Another patient, who had received
treatment of recurrent stenosis before CABG, had recur-
rent chest pain 16 months after repeat angioplasty. A
duplex scan of the stented left subclavian artery obtained at
the first follow-up visit was normal. The patient subse-
quently was seen by her family physician, and no abnormal-
ity was recorded at 1-year follow-up. At this last admission
a blood pressure discrepancy was noted between the right
and left arms. The diagnosis of recurrent coronary steal was
established at arteriography, and 70% recurrent left SAS was
demonstrated. In addition, 50% stenosis was identified at
Table I. Comorbid conditions
Condition n %
Coronary artery disease 14 100
Hypertension 10 71.4
Cerebrovascular disease 6 42.8
Peripheral vascular disease
(other than subclavian artery)
5 35.7
Diabetes mellitus 5 35.7
Chronic renal insufficiency 2 14.2
Smoking history 7 50
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the distal anastomosis of a coronary saphenous vein graft to
the posterior descending artery. Both stenoses were suc-
cessfully treated with angioplasty, with prompt resolution
of symptoms of angina. In a third patient, mildly increased
velocity was demonstrated throughout the left stented sub-
clavian artery on the first postoperative duplex scan, which
remained unchanged on successive control scans, and the
patient has had no symptoms after 3 years. The rate of
significant recurrent stenosis (50%) for all endovascular
interventions performed to prevent or treat coronary steal
was 15.3%; assisted primary patency rate was 100%. Life-
table analysis is depicted in Table II.
Five additional patients have had symptoms of angina
during follow-up, but none could be attributed to coro-
nary-subclavian steal. Three patients underwent percutane-
ous coronary interventions; in the other two patients results
of nuclear stress testing were normal, and coronary arte-
riography was not performed. None of these patients had
left SAS at clinical examination. One patient who had
received prophylactic treatment was lost to follow-up at 6
months, and another who received treatment of coronary
steal was last seen after a 2-year follow-up visit.
DISCUSSION
Coronary-subclavian steal syndrome has been known
for several decades, with early case reports appearing in the
literature in the 1970s.8,10 The dangerous nature of this
syndrome has been acknowledged, and the importance of
its detection before use of the internal mammary artery in
CABG procedures has been emphasized. Development of
coronary subclavian steal less than a year after coronary
revascularization with an in situ internal mammary artery
graft suggests that SAS was probably missed at CABG.
Physical examination remains the most commonly used
screening method. A significant discrepancy in blood pres-
sure between the right and left arms or presence of a
supraclavicular bruit should raise clinical suspicion and
prompt further evaluation with duplex scanning and an-
giography. However, a bruit may not be present, and blood
pressure in the arms may be nearly equal because of abun-
dant collateral vessels around the shoulder. This has led
some investigators to suggest the addition of routine sub-
clavian arteriography at cardiac catheterization.10 Argu-
ments against such practice have been the low reported
incidence (0.44%) of coronary-subclavian steal after
CABG8 and the uncommon association between coronary
artery disease and SAS in patients undergoing CABG.23
In this series, coronary steal occurred between 2 and 31
years after CABG (on average, 14 years). This suggests that
these subclavian artery occlusive lesions most likely devel-
oped after left internal mammary artery grafting. Since
most patients in the post-CABG group had undergone
CABG at other institutions, it is difficult for us to estimate
the incidence of coronary-subclavian steal after CABG on
the basis of our own experience. Significant SAS (50%)
was detected before CABG in four patients, and in one
patient significant recurrent stenosis was detected and
treated before CABG, for a combined incidence of 0.29% at
this institution in this patient group. Although only one
patient in the pre-CABG group had no symptoms, the
diagnosis was suspected on the basis of clinical findings and
confirmed at angiography. In the pre-CABG group, one
patient is being followed up because of asymptomatic re-
current stenosis, and one patient has returned with coro-
nary steal after prophylactic management of recurrent left
SAS before CABG.
In the early and late 1980s carotid-subclavian artery by-
pass grafting was considered the procedure of choice for
treatment of coronary-subclavian steal.24 Several reports have
documented the excellent patency rate of carotid-subclavian
bypass grafting with synthetic materials, its minimal operative
risks, and its excellent durability.25-28 In the early 1990s
endovascular management with balloon angioplasty of SAS
was suggested for prevention or treatment of coronary-sub-
clavian steal.17,29 However, the largest series of subclavian
angioplasty procedures performed to treat SAS has demon-
strated a high rate of recurrent stenosis, averaging 13% to
16%.30-32 Overall results with primary stent deployment have
been more favorable, with a remarkably low rate of early
recurrent stenosis.20,33,34 In our series of 14 patients with
combined coronary and subclavian artery disease, 1 patient
underwent PTA only, another patient underwent angioplasty
to treat stent recurrent stenosis before CABG, and 11 patients
underwent PTA and stenting of SAS, with a technical success
rate of 92.8%. One occluded subclavian vessel could not be
recanalized, and the patient underwent carotid-subclavian
bypass grafting. At mean follow-up of 29 months (median,
33.6 months), two patients have demonstrated significant
recurrent stenosis with associated symptoms, and have under-
gone repeat angioplasty, for a significant recurrent stenosis
rate of 15.3%, which is high; however, assisted primary pa-
tency rate was 100%, comparable to the greater than 90%
long-term primary patency rate reported after surgical revas-
cularization.27,28
This series is certainly too small to enable any definite
conclusion. In a previous analysis of 69 consecutive patients
with SAS and occlusion treated with PTA and stenting by
two of the authors (J.A.R., E.B.D.) at another hospital,20
76 stents were implanted in 69 patients, with a procedural
success rate of 96%. Life table analysis demonstrated an
overall primary patency rate of 73% and overall secondary
patency rate of 90%. Sullivan et al35 also reported excellent
Table II. Life-table analysis for 13 patients with left
subclavian artery stenosis treated with endovascular
therapy to prevent or treat coronary-subclavian steal
syndrome
Year
Normal
patency
Standard
error
95% Confidence
interval
1 0.9200 0.0767 0.553-0.988
2 0.8232 0.1145 0.454-0.953
3 0.6735 0.1646 0.265-0.889
4 0.6735 0.1646 0.26-0.889
5 0.6735 0.1646 0.26-0.889
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primary results with angioplasty and stenting to treat sub-
clavian artery occlusive lesions, and 90% patency at 1 year.
Results of these larger series seem to indicate overall slight
superiority of surgical bypass grafting in experienced hands.
However, absence of any occlusion during follow-up in our
series, however small, suggests that endovascular manage-
ment of SAS may be an excellent alternative to surgical
bypass grafting if an adequate surveillance program can be
established, enabling early detection and treatment of any
significant recurrent stenosis, with comparable long-term
patency rates. The relative simplicity of this endovascular
procedure and the associated low periprocedural morbidity
and complications may favor its use over surgical bypass
grafting for most symptomatic proximal subclavian artery
stenoses, despite absence of comparative long-term pro-
spective randomized data.16-18
Only a decade ago, presence of significant SAS was
considered a formal contraindication to use of the internal
mammary artery in coronary artery bypass grafting, despite
its proved superiority as a bypass conduit. Today PTA and
stenting have become an acceptable mode of therapy, ei-
ther to treat coronary-subclavian steal or to ensure ade-
quate flow to the ipsilateral internal mammary artery before
or during CABG. Perhaps a multicenter prospective ran-
domized trial may best determine whether endovascular
management of this uncommon problem provides durabil-
ity and effectiveness comparable to that with surgical bypass
grafting.
We thank Christopher Wendel, Southern Arizona VA
Health Care System, for input during statistical analysis.
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INVITED COMMENTARY
R. James Valentine, MD
More than 510,000 coronary bypass operations are performed
each year in the United States, but few institutions have had more
than occasional experience with coronary-subclavian steal syn-
drome. In one of the largest series of cases to date, Westerband and
colleagues, who are noted endovascular specialists, champion en-
dovascular treatment of coronary-subclavian steal. They report a
92% technical success rate, 84% primary patency rate, and 100%
assisted patency rate after left subclavian artery interventions.
However, when the data are scrutinized, the results may be less
compelling. The follow-up was not rigorous, and objective vascu-
lar tests were not performed. Mean follow-up was 29 months, and
only seven patients have been followed for more than 3 years.
Within this time frame, 3 of 13 patients undergoing endovascular
therapy have had recurrent subclavian stenosis—symptomatic in 2
patients and asymptomatic in 1 patient—for a recurrence rate of
23%. This should not be surprising, given the 3-year angioplasty
patency rate of 73% reported for endovascular treatment of all
subclavian lesions at the Arizona Heart Institute.1 These results are
also in keeping with the long-term patency rate of 70% to 84%
reported by others.
In comparison, carotid-subclavian bypass grafting is associated
with superior results. Experienced surgical groups have reported
5-year primary patency rate of 92% to 98%.2 However, operative
morbidity and mortality have generally been higher compared with
those at angioplasty. Experience with bypass grafting to treat
coronary-subclavian steal is sparse. In the only other relatively large
series of patients, all 12 patients who underwent carotid-subclavian
bypass grafting survived the operation, and all grafts were patent at
a mean of 29 months.3
What, then, is the best way to treat coronary-subclavian steal?
The dilemma balances on the trade-off between perioperative risk
and long-term results. Reduced perioperative risk clearly favors
endovascular therapy, whereas primary patency is superior after
open operation. In this population, long-term patency may be the
more important issue. Although the vast majority of recurrent
lesions can be treated at repeat angioplasty, averting this potentially
lethal problem is far preferable to repeat treatment.
In the final analysis, treatment recommendations must await
further experience with larger groups of patients who have been
followed up longer. At present, endovascular therapy seems to be
most appropriate in patients at high operative risk and with limited
life expectancy.
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